The way we make medicines is failing people while pharmaceutical companies report record high profits. UAEM believes there is another way.
We aim to create wider support among students, researchers, university administrators and politicians, for a reformed Research and Development (R&D) system that is driven by global health needs and that promotes equitable access to medicines. UAEM has traditionally tackled this goal in a bottom-up, campus based approach – aiming to change individual university practices and norms. Increasingly, we have realized that in order to achieve big picture change, we also need to change norms and practices at a very high, overarching level. This is why we have started urging institutions including the World Health Organization, to advocate for the negotiation of a global R&D agreement.
UAEM aims to create wider support among students, researchers, university administrations and politicians, towards a reformed Research and Development (R&D) system that is driven by global health needs and promotes equitable access to medicines. In 2015 UAEM launched a campaign in support of a global R&D agreement.
WATCH: UAEM’s short video about “How to fix the Research and Development system”
A global Research & Development Agreement could cover the following key points:
- A binding commitment of WHO Member States to ensure sustainable funding for R&D based on global health needs.
- A commitment to use alternative mechanisms that do not rely on high prices to finance and incentivize true innovation.
- Provisions to encourage sharing of knowledge and collaboration between researchers and across borders, enhancing the speed and efficiency of innovation.
As part of the campaign, UAEM launched an academic sign-on letter to call on WHO member states to begin negotiations on a Global R&D Agreement. UAEM continues to engage with politicians and delegates to the WHO on this pressing matter.
For more information on how to support this campaign and get engaged complete this form.
Main advocacy tools
- Sign-on letter
- Re:Route Mapping
- General Policy brief for the 2015-16 campaign for a Global R&D Agreement
Interventions, activities and reactions by UAEM at WHO meetings
- GSPOA Intervention at the 70th World Health Assembly (22-31 May 2017)
- CEWG Intervention at the 70th World Health Assembly (22-31 May 2017)
- Cancer Prevention & Control Intervention at the 70th World Health Assembly (22-31 May 2017)
- Shortage of Medicines Intervention at the 70th World Health Assembly (22-31 May 2017)
- UAEM’s reaction to WHA69 CEWG resolution. WHA69 CEWG resolution.
- CEWG Policy Brief at the 69th World Health Assembly (23-28 May 2016)
- CEWG Intervention at the 69th World Health Assembly (23-28 May 2016)
- Intervention at the Open ended meeting on the Follow up to the CEWG report (2-4 May 2016)
- CEWG Intervention at the 138th WHO Executive Board meeting (25-30 Jan 2016)
- CEWG Policy Brief at the 138th WHO Executive Board meeting (25-30 Jan 2016)
UAEM’s submissions to the UN High Level Panel on Access to Medicines
- Submission on the Re:Route report findings on alternative biomedical R&D initiatives
- Submission with another 25 european access to medicines NGOs, asking for a new R&D system via an R&D Agreement
- Submission on Global access licensing policies for Universities and Public Research Institutions
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.